![]() |
市場調査レポート
商品コード
1521154
バイオリアクターの市場レポート:タイプ別、用途別、規模別、制御タイプ別、地域別、2024年~2032年Bioreactor Market Report by Type (Glass, Stainless Steel, Single-Use), Usage (Lab-Scale Production, Pilot-Scale Production, Full-Scale Production), Scale (5L-20L, 20L-200L, 200L-1500L, Above 1500L), Control Type (Manual, Automated), and Region 2024-2032 |
||||||
カスタマイズ可能
|
バイオリアクターの市場レポート:タイプ別、用途別、規模別、制御タイプ別、地域別、2024年~2032年 |
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2~3営業日
|
世界のバイオリアクターの市場規模は2023年に72億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに186億米ドルに達し、2024年から2032年の間に10.9%の成長率(CAGR)を示すと予測しています。予防ワクチンのニーズの高まりとともに、効果的な治療薬の採用が増加していることが、主に市場を後押ししています。
主な市場促進要因糖尿病やがんなどの慢性疾患の有病率が特に高齢者人口の間で上昇していることが、市場を強化する要因の1つです。さらに、各国におけるバイオ医薬品の製造能力の拡大も重要な成長促進要因となっています。
主要市場動向:最小限のコストとエネルギー要件で微生物操作の形成の柔軟性、品質、拡張性を最適化するシングルユース・バイオリアクター(SUB)の開拓を含む数多くの技術的進歩は、市場全体を刺激する新興国動向のひとつです。
競合情勢:世界市場の著名企業には、2mag AG、bbi-biotech GmbH、Bioengineering AG、Eppendorf SE、Getinge AB、Infors AG、Merck KGaA、Pall Corporation(Danaher Corporation)、Sartorius AG、Solaris Biotechnology Srl、Thermo Fisher Scientific Inc.などがあります。
地理的動向:北米は研究開発活動に力を入れており、現在同市場において明確な優位性を示しています。これとは別に、持続可能で費用対効果の高い生産方法を支援するために、政府機関が有利な政策を打ち出していることも、市場に好結果をもたらしています。
課題と機会:一貫した製品の品質と拡張性に関する業界関係者の懸念の高まりが、市場の成長を妨げています。しかし、バイオプロセスを最適化し、再現性を高めるための高度なモニタリング・制御技術の統合が進んでいることは、予測期間を通じて世界市場を活性化し続けるであろう。
シングルユース・バイオリアクターの利用
シングルユース・バイオリアクター(SUB)は、柔軟性、費用対効果、汚染リスクの低減などの利点により、広く普及しています。これが市場を刺激しています。IMARCによると、世界のシングルユース・バイオリアクター市場規模は2023年に34億米ドルに達しました。今後、IMARC Groupは、市場が2032年までに111億米ドルに達し、2024年から2032年の間に13.8%の成長率(CAGR)を示すと予測しています。さらに、従来のステンレス製バイオリアクターとは異なり、SUBは使い捨てのバッグを採用しているため、バッチ間の大掛かりな洗浄や滅菌の必要がないです。2023年12月、セレクサスは、細胞の迅速な増殖のために最適なエアレーションを提供するエアリフト使い捨てバイオリアクターシステムを発表しました。この穏やかな撹拌方法は、通常、微生物発酵や細胞培養に適しています。これ以外にも、主要プレーヤーは革新的なSUB設計を生産しており、小規模研究と大規模生産の両方のニーズに応えており、これがバイオリアクターの市場の展望を後押ししています。例えば、2024年2月、開発・製造受託機関(CDMO)であるWuXi Biologics社は、アイルランドに約3億2,500万ユーロを投資し、約54,000Lの使い捨てバイオリアクター容量を持つシングルユースサイトを建設すると発表しました。さらに、2024年3月、サーモフィッシャーサイエンティフィック(TM)は、HyPerforma(TM)シングルユース・バイオリアクター(SUB)製品プラットフォームのアプリケーションに特化した一連の機能強化を発表しました。同様に、2024年3月には、Distek, Inc.が哺乳類細胞増殖と組換えタンパク質生産用のシングルユース・バイオリアクター(SUB)システムを発表しました。さらに、著名企業間の継続的な提携は、今後数年間で市場を拡大すると予測されています。例えば、2024年6月、Aragen Bioscience社とGetinge社は、後者のシングルユース生産リアクター(SUPR)の検証に成功したと発表しました。これに伴い、この提携はGetingeの革新的なシングルユース技術とAragenのバイオ医薬品製造に関する専門知識を組み合わせたものです。
オートメーションの進歩
バイオリアクターに新しい制御システムと自動化を広く統合することで、pH、温度、溶存酸素などの重要なパラメーターを正確に制御し、リアルタイムでモニタリングすることが可能になり、バイオプロセスに革命をもたらしています。これは重要な成長促進要因として作用しています。例えば、2023年8月、Repligen CorporationとSartoriusは、統合されたプロセス分析技術(PAT)と定義済みの高度な制御レシピを提供する完全互換の組込み型XCell ATFソフトウェアとハードウェアモジュールで構成される統合バイオリアクターシステムを発表しました。さらに、このシステムは、細胞保持コントロールタワーを別途使用することなく、灌流プロセスにおける細胞増殖のコントロールと細胞保持の強化を合理化した方法でユーザーに提供することを目的としています。このほか、バイオテクノロジー・ソリューションのイノベーターの1つであるオートメイテッド・コントロール・コンセプツ(ACC)は、2023年9月、最先端のバイオリアクター制御・データプラットフォームであるLab Owlを発表しました。このプラットフォームは、複数のプロセスパラメーターの調整と正確なモニタリングを可能にし、一貫した再現性のある結果をもたらします。これとは別に、カルトザイムは2023年12月、AI、ハードウェア、クラウドコンピューティングを搭載したバイオリアクター・インテリジェント・オペレーション・ナノテクノロジー(BION)システムを発売し、バイオ製造プロセスを制御し、より効率的かつ最小限のコストで一貫した成果を達成します。さらに、実験室規模から生産規模へのシームレスなスケールアップを促進し、多数のバイオリアクターサイズにわたって一貫した性能を確保するのに役立つため、高度な制御システムに対する需要が高まっていることも、バイオリアクターの市場の収益を増加させています。例えば、2024年4月、カルチュア・バイオサイエンシズは、チャイニーズハムスター卵巣(CHO)細胞用に設計された高度な制御システムとリアルタイムモニタリング機能を備えたバイオリアクターを開発しました。
持続可能なバイオプロセスの開発
持続可能性は市場において重要な検討事項となってきています。有力企業はエネルギー消費と廃棄物発生を最小限に抑えることに注力しており、これが市場成長を刺激しています。2023年10月、奈良先端科学技術大学院大学と藤田大学の研究チームは、コンピュータによるフィードフォワード制御と遺伝子組み換え生細胞をシームレスに統合したハイブリッド・イン・シリコ/イン・セル・コントローラー(HISICC)を発表しました。この他、2023年11月、ADMとソルーゲンは戦略的パートナーシップを結び、既存の化石燃料ベースの材料に代わる分子を開発し、低炭素有機酸の製品ラインを拡大するため、約50万ft2のバイオ製造施設を建設します。さらに、バイオリアクターメーカーは、より効率的な混合・曝気システムなど、バイオリアクター設計におけるいくつかの革新的技術に投資しており、環境に優しいバイオプロセシング・ソリューションの人気を高めています。例えば、ベーリンガーインゲルハイムは、環境の持続可能性に重点を置いたアニマルヘルス分野のバイオプロセス技術を提供しています。これに伴い、抗原生物学的製剤製造のためのプロセスチェーンの最適化から、現行の慣行に関する継続的な議論と評価に至るまで、同社は環境フットプリントの最小化に強くコミットしています。さらに、2024年3月、英国研究革新庁(UKRI)は、国内全域で持続可能なバイオ製造の進歩を推進するための21の分野横断的共同研究を発表しました。
The global bioreactor market size reached US$ 7.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.6 Billion by 2032, exhibiting a growth rate (CAGR) of 10.9% during 2024-2032. The increasing adoption of effective treatment drugs, along with the rising need for preventive vaccines, is primarily propelling the market.
Major Market Drivers: The rising prevalence of chronic diseases, including diabetes and cancer, particularly among the geriatric population, is one of the factors bolstering the market. Moreover, the growing biopharmaceutical manufacturing capacities across various countries are also acting as significant growth-inducing factors.
Key Market Trends: Numerous technological advancements, including the development of single-use bioreactors (SUBs) for optimizing the flexibility, quality, and scalability of the formation of microorganism operations with minimal cost and energy requirements, are among the emerging trends stimulating the overall market.
Competitive Landscape: Some of the prominent companies in the global market include 2mag AG, bbi-biotech GmbH, Bioengineering AG, Eppendorf SE, Getinge AB, Infors AG, Merck KGaA, Pall Corporation (Danaher Corporation), Sartorius AG, Solaris Biotechnology Srl, and Thermo Fisher Scientific Inc., among many others.
Geographical Trends: North America currently exhibits a clear dominance in the market, on account of the region's strong emphasis on R&D activities. Apart from this, the launch of favorable policies by government bodies to support sustainable and cost-effective production methods is further creating a positive outcome for the market.
Challenges and Opportunities: The elevating concerns among industry players regarding consistent product quality and scalability are hindering the market growth. However, the increasing integration of advanced monitoring and control technologies to optimize bioprocesses and enhance reproducibility will continue to catalyze the global market over the forecasted period.
Usage of Single-Use Bioreactors
Single-use bioreactors (SUBs) are gaining extensive popularity, owing to their benefits, such as flexibility, cost-effectiveness, reduced risk of contamination, etc. This, in turn, is stimulating the market. According to the IMARC, the global single-use bioreactors market size reached US$ 3.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.1 Billion by 2032, thereby exhibiting a growth rate (CAGR) of 13.8% during 2024-2032. Moreover, unlike traditional stainless-steel bioreactors, SUBs adopt disposable bags, which aids in eliminating the need for extensive cleaning and sterilization between batches. In December 2023, Cellexus introduced airlift single-use disposable bioreactor systems that offer optimal aeration for the rapid growth of cells. This method of gentle agitation is usually suitable for microbial fermentation and cell culture. Besides this, key players are also producing innovative SUB designs, catering to both small-scale research and large-scale production needs, which is fueling the bioreactor market outlook. For instance, in February 2024, the contract development and manufacturing organization (CDMO), WuXi Biologics, announced the construction of a single-use site with approximately 54,000 L of disposable bioreactor capacity via an investment of roughly €325 Million in Ireland. Additionally, in March 2024, Thermo Fisher Scientific(TM) launched a series of application-specific enhancements to the HyPerforma(TM) single-use bioreactor (SUB) product platform, each tailored to the unique requirements of intensified fed-batch, perfusion, and adherent cell cultures. Similarly, in March 2024, Distek, Inc. unveiled a single-use bioreactor (SUB) system for mammalian cell growth and recombinant protein production. Furthermore, continuous collaborations among prominent companies are projected to augment the market in the coming years. For example, in June 2024, Aragen Bioscience and Getinge announced the successful validation of the latter's single-use production reactors (SUPR). In line with this, the collaboration combined Getinge's innovative single-use technology and Aragen's expertise in biopharmaceutical manufacturing.
Advancements in Automation
The widespread integration of novel control systems and automation with bioreactors is revolutionizing bioprocessing by enabling precise control over critical parameters, such as pH, temperature, dissolved oxygen, etc., and real-time monitoring. This is acting as a significant growth-inducing factor. For instance, in August 2023, Repligen Corporation and Sartorius introduced an integrated bioreactor system that comprises a fully compatible embedded XCell ATF software and hardware module offering predefined advanced control recipes with integrated process analytical technology (PAT). Additionally, the system aims to provide users with a streamlined way to control cell growth and enhance cell retention in perfusion processes without utilizing a separate cell retention control tower. Besides this, in September 2023, Automated Control Concepts (ACC), one of the innovators in biotechnology solutions, released its cutting-edge bioreactor control and data platform, Lab Owl, that allows for adjustment of multiple process parameters and precise monitoring, resulting in consistent and reproducible outcomes. Apart from this, in December 2023, Cultzyme launched a bioreactor intelligent operative nanotechnology (BION) system equipped with AI, hardware, and cloud computing to control the biomanufacturing process and achieve consistent outcomes more efficiently and at minimal costs. Furthermore, the escalating demand for advanced control systems, as they facilitate seamless scale-up from laboratory to production scale, which aids in ensuring consistent performance across numerous bioreactor sizes, is also increasing the bioreactor market revenue. For instance, in April 2024, Culture Biosciences created bioreactors with advanced control systems and real-time monitoring capabilities designed to accommodate Chinese Hamster Ovary (CHO) cells.
Development of Sustainable Bioprocessing
Sustainability is becoming a critical consideration in the market. Prominent players are focusing on minimizing energy consumption and waste generation, which is stimulating the market growth. In October 2023, a team of researchers at the Nara Institute of Science and Technology and Fujita University introduced a hybrid in silico/in-cell controller (HISICC) that seamlessly integrates computerized feedforward control with genetically modified living cells, offering the potential for cost-effective and eco-friendly chemical and fuel production. Besides this, in November 2023, ADM and Solugen formed a strategic partnership to build an approximately 500,000-ft2 biomanufacturing facility to develop molecules to replace existing fossil fuel-based materials and scale its line of lower-carbon organic acids. Moreover, bioreactor manufacturers are investing in several innovations in bioreactor design, such as more efficient mixing and aeration systems, which is elevating the popularity of greener bioprocessing solutions. For example, Boehringer Ingelheim offers bioprocess technology operations in animal health with an improved focus on environmental sustainability. In line with this, from continuously discussing and evaluating current practices to optimizing process chains for antigenic biological manufacturing, the company is strongly committed to minimizing its environmental footprint. Additionally, in March 2024, the UK Research and Innovation (UKRI) announced 21 cross-sector collaborations to drive advancements in sustainable biomanufacturing across the country.
IMARC Group provides an analysis of the key trends in each segment of the market, along with the bioreactor market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on the type, usage, scale, and control type.
Glass
Stainless Steel
Single-Use
Among these, single-use currently exhibit a clear dominance in the market
The report has provided a detailed breakup and analysis of the market based on the type. This includes glass, stainless steel, and single-use. According to the report, single-use represented the largest market segmentation.
A single-use bioreactor (SUB) is widely utilized, as it is flexible and easy to use and install. Moreover, it minimizes the risk of cross-contamination, reduces labor costs, eliminates the cleaning process and validation issues, etc., thereby propelling the segment's growth. For example, in March 2024, ABEC introduced a single-use bioreactor system for cell culture production. Additionally, in February 2024, MilliporeSigma developed three Mobius(R) products that deliver improved efficiency and ease of use for biopharmaceutical manufacturing workflows. In line with this, variants include a 2000-liter mixing system for difficult-to-mix biopharm ingredients, a single-use bioreactor with an industry-leading design, and a liquid transport system for non-aseptic and aseptic substances.
Lab-Scale Production
Pilot-Scale Production
Full-Scale Production
Currently, pilot-scale production holds the largest bioreactor market share
The report has provided a detailed breakup and analysis of the market based on the usage. This includes lab-scale production, pilot-scale production, and full-scale production. According to the report, pilot-scale production represented the largest market segmentation.
Pilot-scale production in bioreactors serves as a crucial intermediary step between laboratory research and full-scale manufacturing in the biopharmaceutical industry. This phase allows for the optimization of bioprocesses on a scale that closely mimics commercial production, providing valuable insights into process performance, scalability, and reproducibility. Pilot-scale bioreactors typically range from 50 to 500 liters in capacity. For instance, in January 2024, San Francisco-based SciFi Foods announced the successful completion of its first commercial bioreactor facility in San Leandro, California. They are used to test and refine production parameters such as cell growth, nutrient consumption, and product yield under conditions that replicate those of large-scale operations. Additionally, pilot-scale production facilitates regulatory compliance by generating data required for process validation and quality assurance. Companies like GE Healthcare and Sartorius offer advanced pilot-scale bioreactor systems equipped with sophisticated monitoring and control technologies, enabling precise control over critical process parameters and ensuring a seamless transition to large-scale manufacturing.
5L-20L
20L-200L
200L-1500L
Above 1500L
The report has provided a detailed breakup and analysis of the market based on the scale. This includes 5l-20l, 20l-200l, 200l-1500l, and above 1500l.
Bioreactors are designed in various scales to meet the needs of different stages of bioprocessing, from research and development to full-scale commercial production. Small-scale bioreactors, typically ranging from 5L to 20L, are primarily used in laboratory settings for early-stage research, process development, and small-batch production. As per the bioreactor market statistics, they are essential for optimizing cell culture conditions and conducting preliminary studies. Medium-scale bioreactors, with capacities between 20L and 200L, serve as a bridge between laboratory research and pilot-scale production, allowing for the refinement of bioprocesses and scaling up experiments to a semi-industrial level. Bioreactors in the 200L to 1500L range are used for pilot-scale production, providing a realistic simulation of commercial-scale operations and facilitating the validation of production processes. Finally, bioreactors with capacities above 1500L are employed in full-scale commercial production, capable of producing large volumes of biologics, vaccines, and other biopharmaceutical products. For instance, in March 2024, Syngene International, a global contract research, development, and manufacturing organization (CRDMO), introduced a biologics facility with five 2000L single-use bioreactors in Bangalore, India.
Manual
Automated
Currently, automated holds the largest bioreactor market share
The report has provided a detailed breakup and analysis of the market based on the control type. This includes manual and automated. According to the report, automated represented the largest market segmentation.
Automated bioreactors are revolutionizing bioprocessing by integrating advanced control systems that enhance precision, efficiency, and scalability. They allow for real-time monitoring and control of critical parameters, including temperature, pH, dissolved oxygen, etc. The system's automation capabilities minimize human intervention, thereby reducing the risk of contamination and errors while optimizing cell growth and product yield. For example, in May 2024, a team of researchers at Florida International University developed an automated 3D-printed bioreactor to grow bone in the lab. Additionally, biopharmaceutical manufacturers offer versatile and robust solutions to enhance productivity and maintain high standards of quality and compliance. For instance, in September 2023, Automated Control Concepts (ACC), one of the leading innovators in biotechnology solutions, announced the development of its cutting-edge bioreactor control and data platform, Lab Owl, to redefine the landscape of bioprocessing.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America currently dominates the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The North America bioreactor market is witnessing robust growth, fueled by the region's strong emphasis on biopharmaceutical research, development, and manufacturing. Additionally, advancements in bioprocessing technologies, such as single-use bioreactors and automation, are enhancing the efficiency and scalability of biomanufacturing processes. The presence of major pharmaceutical and biotechnology companies, coupled with supportive government initiatives and funding, is further propelling the bioreactor market demand. In February 2024, Thermo Fisher Scientific expanded its manufacturing capacity at its Missouri, U.S. site to produce complex biologic treatments for a range of diseases, including cancer, autoimmune conditions, and rare disorders. Furthermore, the North America bioreactor market is poised for continued growth, driven by technological advancements and increasing biopharmaceutical production demands. For instance, in March 2023, Micro Digital Co. signed a formal contract to supply bioreactors to expand its presence in North America.
2mag AG
bbi-biotech GmbH
Bioengineering AG
Eppendorf SE
Getinge AB
Infors AG
Merck KGaA
Pall Corporation (Danaher Corporation)
Sartorius AG
Solaris Biotechnology Srl
Thermo Fisher Scientific Inc.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
June 2024: Aragen Bioscience and Getinge announced the successful validation of the latter's single-use production reactors (SUPR) for large-scale recombinant antibody manufacturing.
May 2024: Multiply Labs, one of the robotics companies developing automated manufacturing systems to produce individualized drugs, and Wilson Wolf collaborated to automate Wilson Wolf's G-Rex(R) bioreactors for cell therapy manufacturing.
May 2024: A team of researchers at Florida International University introduced an automated 3D-printed bioreactor to grow bone in the lab.